University of Indonesia
Jakarta Pusat, DKI Jakarta, 10440, Indonesia
NCT Number: NCT04509141
Migraine is a primary headache attack, specific, paroxysmal, with or without aura, with subjective manifestations both before and after the attack, a chronic type of headache with symptoms of recurrence, attacks at productive age and can cause a decrease in work productivity up to 80%, so that it will affect the quality of life, economic life and education globally which leads to losses for migraine sufferers and institutions where migraine sufferers attend school, work and in the lives of sufferers' families.
Looking for future studies?
Notify Me19 year–50 year
All sexes
Interventional
Not applicable
Jakarta Pusat, DKI Jakarta, 10440, Indonesia
Migraine is a primary headache attack, specific, paroxysmal, with or without aura, with subjective manifestations both before and after the attack, a chronic type of headache with symptoms of recurrence, attacks at productive age and can cause a decrease in work productivity up to 80%, so that it will affect the quality of life, economic life and education globally which leads to losses for migraine sufferers and institutions where migraine sufferers attend school, work and in the lives of sufferers' families. With the high prevalence and disability rates for migraine sufferers, on the other hand, the right treatment for migraine has not yet been obtained to the maximum, it is necessary to deepen the treatment and prevention of migraine is needed, and until now there has been no definitive cure, both for prevention and treatment, so it is necessary to develop therapies that can provide more accurate relief for migraine sufferers. The purpose of this study is to assess the success in managing migraine in reducing the frequency of attacks, reducing the intensity of attacks and reducing the duration of attacks from weeks 0, 4 to 8
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
acupuncture points used were EXHN5 Taiyang, GB20 Fengchi, TE5 Waigun, GB41 Zulinqi
Time frame: at week 4
Manual acupuncture interventions can reduce the frequency of migraine attacks better than the preventive pharmacological valproic acid
Time frame: at week 4
Manual acupuncture interventions can reduce the duration of migraine attacks better than the preventive pharmacological valproic acid
Time frame: at week 4
Manual acupuncture interventions can reduce the change from Baseline in pain scores on the Visual Analog Scale of migraine attacks better than the preventive pharmacological valproic acid
Time frame: at week 8
Manual acupuncture interventions can reduce the frequency of migraine attacks better than the preventive pharmacological valproic acid
Time frame: at week 8
Manual acupuncture interventions can reduce the duration of migraine attacks better than the preventive pharmacological valproic acid
Time frame: at week 8
Manual acupuncture interventions can reduce the change from Baseline in pain scores on the Visual Analog Scale of migraine attacks better than the preventive pharmacological valproic acid
Indonesia University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03472092
Brain Diseases, Central Nervous System Diseases
Cincinnati, Ohio, United States
View Trial DetailsNCT04715685
Brain Diseases, Central Nervous System Diseases
Aurora, Colorado, United States
View Trial DetailsNCT05415020
Brain Diseases, Central Nervous System Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT05889624
Brain Diseases, Central Nervous System Diseases
Birmingham, Alabama, United States
View Trial Details